Literature DB >> 9624169

Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase.

T Yamauchi1, Y Kaburagi, K Ueki, Y Tsuji, G R Stark, I M Kerr, T Tsushima, Y Akanuma, I Komuro, K Tobe, Y Yazaki, T Kadowaki.   

Abstract

Growth hormone (GH) and prolactin (PRL) binding to their receptors, which belong to the cytokine receptor superfamily, activate Janus kinase (JAK) 2 tyrosine kinase, thereby leading to their biological actions. We recently showed that GH mainly stimulated tyrosine phosphorylation of epidermal growth factor receptor and its association with Grb2, and concomitantly stimulated mitogen-activated protein kinase activity in liver, a major target tissue. Using specific antibodies, we now show that GH was also able to induce tyrosine phosphorylation of insulin receptor substrate (IRS)-1/IRS-2 in liver. In addition, the major tyrosine-phosphorylated protein in anti-p85 phosphatidylinositol 3-kinase (PI3-kinase) immunoprecipitate from liver of wild-type mice was IRS-1, and IRS-2 in IRS-1 deficient mice, but not epidermal growth factor receptor. These data suggest that tyrosine phosphorylation of IRS-1 may be a major mechanism for GH-induced PI3-kinase activation in physiological target organ of GH, liver. We also show that PRL was able to induce tyrosine phosphorylation of both IRS-1 and IRS-2 in COS cells transiently transfected with PRLR and in CHO-PRLR cells. Moreover, we show that tyrosine phosphorylation of IRS-3 was induced by both GH and PRL in COS cells transiently transfected with IRS-3 and their cognate receptors. By using the JAK2-deficient cell lines or by expressing a dominant negative JAK2 mutant, we show that JAK2 is required for the GH- and PRL-dependent tyrosine phosphorylation of IRS-1, -2, and -3. Finally, a specific PI3-kinase inhibitor, wortmannin, completely blocked the anti-lipolytic effect of GH in 3T3 L1 adipocytes. Taken together, the role of IRS-1, -2, and -3 in GH and PRL signalings appears to be phosphorylated by JAK2, thereby providing docking sites for p85 PI3-kinase and activating PI3-kinase and its downstream biological effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624169     DOI: 10.1074/jbc.273.25.15719

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: involvement of insulin receptor substrate-related adapter proteins.

Authors:  K Nishigaki; C Hanson; T Ohashi; D Thompson; K Muszynski; S Ruscetti
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  A pathway map of prolactin signaling.

Authors:  Aneesha Radhakrishnan; Rajesh Raju; Nirvana Tuladhar; Tejaswini Subbannayya; Joji Kurian Thomas; Renu Goel; Deepthi Telikicherla; Shyam Mohan Palapetta; B Abdul Rahiman; Desai Dattatraya Venkatesh; Kulkarni-Kale Urmila; H C Harsha; Premendu Prakash Mathur; T S Keshava Prasad; Akhilesh Pandey; Carrie Shemanko; Aditi Chatterjee
Journal:  J Cell Commun Signal       Date:  2012-06-09       Impact factor: 5.782

3.  Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion.

Authors:  L M Shaw
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

4.  Stimulation of pancreatic beta-cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) with no crosstalk to insulin receptor substrate-mediated mitogenic signalling.

Authors:  S P Cousin; S R Hügl; M G Myers; M F White; A Reifel-Miller; C J Rhodes
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

5.  Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk.

Authors:  Kanji Mori; Frederic Blanchard; Celine Charrier; Severine Battaglia; Kosei Ando; Laurence Duplomb; Leonard D Shultz; Francoise Redini; Dominique Heymann
Journal:  Cancer Sci       Date:  2008-10-18       Impact factor: 6.716

6.  Rutaecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating the IRS-1/PI3K/Akt and AMPK/ACC2 signaling pathways.

Authors:  Xu-qiang Nie; Huai-hong Chen; Jian-yong Zhang; Yu-jing Zhang; Jian-wen Yang; Hui-jun Pan; Wen-xia Song; Ferid Murad; Yu-qi He; Ka Bian
Journal:  Acta Pharmacol Sin       Date:  2016-03-14       Impact factor: 6.150

7.  Transglutaminase-1 protects renal epithelial cells from hydrogen peroxide-induced apoptosis through activation of STAT3 and AKT signaling pathways.

Authors:  Murugavel Ponnusamy; Maoyin Pang; Pavan Kumar Annamaraju; Zhu Zhang; Rujun Gong; Y Eugene Chin; Shougang Zhuang
Journal:  Am J Physiol Renal Physiol       Date:  2009-08-26

8.  JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells.

Authors:  Hui Jin; Nathan J Lanning; Christin Carter-Su
Journal:  Mol Endocrinol       Date:  2008-05-22

9.  Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth.

Authors:  A McGarry Houghton; Danuta M Rzymkiewicz; Hongbin Ji; Alyssa D Gregory; Eduardo E Egea; Heather E Metz; Donna B Stolz; Stephanie R Land; Luiz A Marconcini; Corrine R Kliment; Kimberly M Jenkins; Keith A Beaulieu; Majd Mouded; Stuart J Frank; Kwok K Wong; Steven D Shapiro
Journal:  Nat Med       Date:  2010-01-17       Impact factor: 53.440

10.  Expression and function of the insulin receptor substrate proteins in cancer.

Authors:  Katerina Mardilovich; Shannon L Pankratz; Leslie M Shaw
Journal:  Cell Commun Signal       Date:  2009-06-17       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.